Publications by authors named "K R Fath"

NIMA Related Kinase 2 (Nek2) kinase is an attractive target for the development of therapeutic agents for several types of highly invasive cancers. Despite this, no small molecule inhibitor has advanced to the late clinical stages thus far. In this work, we have identified a novel spirocyclic inhibitor (V8) of Nek2 kinase, utilizing a high-throughput virtual screening (HTVS) approach.

View Article and Find Full Text PDF

Usher syndrome (USH) is the most common form of hereditary deaf-blindness in humans. USH is a complex genetic disorder, assigned to three clinical subtypes differing in onset, course and severity, with USH1 being the most severe. Rodent USH1 models do not reflect the ocular phenotype observed in human patients to date; hence, little is known about the pathophysiology of USH1 in the human eye.

View Article and Find Full Text PDF

Human cathepsin B is a cysteine-dependent protease whose roles in both normal and diseased cellular states remain yet to be fully delineated. This is primarily due to overlapping substrate specificities and lack of unambiguously annotated physiological functions. In this work, a selective, cell-permeable, clickable and tagless small molecule cathepsin B probe, KDA-1, is developed and kinetically characterized.

View Article and Find Full Text PDF
Article Synopsis
  • Human cathepsin L is an important enzyme involved in cellular signaling, and its overexpression is linked to various diseases, including aggressive cancers.
  • There is a need for specific cathepsin L probes to better understand its complex roles before investing in drug development targeted at it.
  • A new probe has been created that is efficient, selective, and non-toxic; it successfully inhibits cathepsin L in a zebrafish model, highlighting its potential for studying cathepsin L's role in both healthy and disease contexts.
View Article and Find Full Text PDF

Nanoscale supramolecular systems have been increasingly gaining importance as drug release vehicles due to their ability to target tumor cells. In this work, we have developed a new class of nanoassemblies derived from the phytosterol 24-EpiBrassinolide (EpiB) for the development of nanocarriers for the anticancer drug Doxorubicin (DOX). EpiB is a biocompatible cholesterol mimic, and has inherent apoptotic properties toward cancer cells.

View Article and Find Full Text PDF